Understanding Prediabetes

Prediabetes is best understood as a transitional phase in the continuum of glucose dysregulation. It occurs when the body's cells begin to lose their sensitivity to insulin, a hormone produced by the beta cells of the pancreas that is essential for moving glucose from the bloodstream into tissues for energy. To compensate for this reduced sensitivity, the pancreas secretes more insulin, leading to a state known as hyperinsulinemia. Over time, the pancreatic beta cells can become exhausted, causing blood glucose levels to rise further. The condition is diagnosed using one of three standard criteria: a fasting plasma glucose level between 100 mg/dL and 125 mg/dL (impaired fasting glucose), a 2-hour plasma glucose level between 140 mg/dL and 199 mg/dL during an oral glucose tolerance test (impaired glucose tolerance), or a hemoglobin A1c level between 5.7% and 6.4%.

Prediabetes is alarmingly common. The Centers for Disease Control and Prevention (CDC) estimates that more than one in three American adults have prediabetes, yet more than 80% of them are unaware of their status. The risk factors overlap heavily with those for type 2 diabetes: overweight or obesity, sedentary lifestyle, family history, history of gestational diabetes, and—critically for this discussion—PCOS. The condition is not benign; it confers a significantly elevated risk of developing diabetes within five to ten years unless effective interventions are implemented. Screening is straightforward and inexpensive, yet it remains underutilized, especially in younger women with PCOS who may not perceive themselves as being at risk.

The connection between PCOS and prediabetes is both strong and bidirectional. Among women with PCOS, the prevalence of prediabetes or type 2 diabetes is substantially higher than in the general female population. Research indicates that up to 50% of women with PCOS will develop prediabetes or type 2 diabetes by the time they reach age 40, compared with a much lower rate in women without the condition. In some studies, the odds of having impaired glucose tolerance are three to seven times higher in women with PCOS, even after controlling for body mass index (BMI). This suggests that PCOS itself—independent of obesity—confers unique metabolic risk.

This elevated risk is not distributed evenly across all women with PCOS. Those with the classic hyperandrogenic phenotype (elevated testosterone, hirsutism, and oligo-ovulation) tend to have the highest rates of insulin resistance and prediabetes. Women with the normoandrogenic phenotype also carry elevated risk, though to a lesser degree. Understanding this heterogeneity is important for clinicians because it helps identify which patients need the most aggressive screening and preventive interventions.

Insulin Resistance as the Core Mechanism

The fundamental driver of this increased risk is insulin resistance. In women with PCOS, insulin resistance is not universally present but is common, affecting approximately 50% to 70% of those with the syndrome, particularly those with a higher BMI or with the classic hyperandrogenic phenotype. The origins of insulin resistance in PCOS are multifactorial. Abnormalities in post-receptor insulin signaling—including decreased tyrosine phosphorylation of the insulin receptor and reduced activity of downstream effectors such as IRS-1 and PI3K—impair the ability of insulin to promote glucose uptake in muscle and adipose tissue. This defect exists even in lean women with PCOS, indicating a genetic or epigenetic predisposition.

In addition, elevated levels of androgens—especially testosterone—exacerbate insulin resistance. Androgens promote the expansion of visceral adipose tissue, which is more metabolically active and pro-inflammatory than subcutaneous fat. This increase in visceral fat further worsens insulin sensitivity through the release of free fatty acids, adipokines, and inflammatory cytokines. Conversely, hyperinsulinemia (resulting from insulin resistance) acts on the ovaries to stimulate androgen production, creating a vicious cycle that worsens both the metabolic and reproductive features of PCOS. This feedback loop explains why addressing insulin resistance is a central therapeutic target in PCOS management.

How Insulin Resistance Affects Women with PCOS

The impact of insulin resistance extends beyond glucose metabolism. In women with PCOS, high circulating insulin levels directly stimulate theca cells in the ovaries to produce more androgens, a process mediated through the insulin-like growth factor-1 (IGF-1) receptor and through amplification of luteinizing hormone (LH) action. This leads to increased ovarian androgen production, worsening acne, hirsutism, and anovulation. Insulin also reduces the hepatic production of sex hormone-binding globulin (SHBG), resulting in higher levels of free, bioavailable testosterone. Low SHBG is a well-documented biomarker of insulin resistance and is commonly seen in PCOS. Measuring SHBG can provide a readily available clinical clue to the presence of underlying metabolic dysfunction.

The metabolic consequences are equally profound. Impaired glucose uptake in skeletal muscle and adipose tissue forces the pancreas to secrete more insulin, driving hyperinsulinemia. Over time, the pancreatic beta cells may fail to keep up, leading to the transition from prediabetes to type 2 diabetes. Women with PCOS also exhibit higher rates of postprandial hyperglycemia, dyslipidemia (elevated triglycerides, low HDL cholesterol), and hypertension compared with age- and weight-matched controls. These metabolic abnormalities contribute to a significantly increased risk of cardiovascular disease, even after accounting for traditional risk factors. The combination of insulin resistance, hyperandrogenism, and chronic low-grade inflammation creates a metabolic milieu that accelerates vascular damage and promotes atherogenesis.

The Role of Obesity

Obesity is a common comorbidity in PCOS, affecting roughly 40% to 80% of women depending on age, ethnicity, and diagnostic criteria. While obesity independently worsens insulin resistance, it is not the sole cause of metabolic dysfunction in PCOS. Studies comparing lean women with PCOS to lean controls consistently show higher rates of prediabetes, impaired glucose tolerance, and metabolic syndrome in the PCOS group. Nevertheless, the additive effect of obesity and PCOS is substantial; women with both conditions have some of the highest rates of prediabetes and diabetes. Weight gain, especially in the abdomen, amplifies insulin resistance, reduces SHBG, and increases free androgen levels, further accelerating the progression from prediabetes to type 2 diabetes. Visceral adiposity is particularly harmful because it releases pro-inflammatory cytokines and free fatty acids that directly impair insulin signaling in muscle and liver tissue.

Other Metabolic Consequences of the PCOS-Prediabetes Connection

Beyond the direct risk of diabetes, the metabolic dysregulation seen in PCOS and prediabetes has wide-ranging implications. Nonalcoholic fatty liver disease (NAFLD) is now recognized as common in PCOS, with studies showing a prevalence of 35% to 60% or higher, depending on the population. Insulin resistance is the key driver; when the liver becomes insulin resistant, it continues to produce glucose and synthesizes triglycerides, which accumulate in hepatocytes. NAFLD can progress to steatohepatitis, fibrosis, and cirrhosis, making it a serious long-term concern. Up to 40% of women with PCOS have elevated liver enzymes, and screening for NAFLD with liver ultrasound or FibroScan should be considered in women with PCOS and metabolic risk factors.

Women with PCOS also face a markedly increased risk of gestational diabetes mellitus (GDM). The insulin resistance that is characteristic of pregnancy is superimposed on an already compromised metabolic state, leading to higher rates of GDM. In fact, a history of PCOS is an independent risk factor for GDM, with at least a two- to threefold increased risk. GDM, in turn, increases the lifetime risk of type 2 diabetes for both mother and child, perpetuating a cycle of metabolic vulnerability across generations. Preconception counseling for women with PCOS should include a discussion of this risk and the importance of optimizing metabolic health before pregnancy.

Cardiovascular disease remains the leading cause of death in women with PCOS, and the prediabetes connection accelerates this risk. Women with PCOS have higher rates of endothelial dysfunction, arterial stiffness, and coronary artery calcification compared with age-matched controls. The combination of insulin resistance, dyslipidemia, hypertension, and chronic inflammation creates a pro-atherogenic state that increases the lifetime risk of myocardial infarction and stroke. Early intervention to improve insulin sensitivity can reduce cardiovascular risk, underscoring the importance of screening and treatment.

Managing the Connection

A proactive, multifaceted approach is essential for preventing the progression from prediabetes to type 2 diabetes in women with PCOS. The goal is to improve insulin sensitivity, reduce hyperinsulinemia, and mitigate the downstream effects on androgen levels and metabolic health. Early intervention is critical because the transition from prediabetes to diabetes is not inevitable; with appropriate management, glucose levels can return to normal.

Lifestyle Interventions

Lifestyle modification remains the cornerstone of management. A moderate weight loss of 5% to 10% of total body weight can significantly improve insulin sensitivity, reduce visceral adiposity, lower testosterone levels, and restore ovulatory function. Dietary changes should emphasize a reduction in refined carbohydrates and added sugars, with an increase in fiber-rich foods, lean protein, and healthy fats. The Mediterranean diet, the DASH diet, or a low-glycemic-index approach all show evidence of benefit. Regular physical activity, including both aerobic exercise and resistance training, enhances glucose uptake, improves insulin signaling, and promotes weight maintenance. The combination of dietary change and exercise produces greater improvements in insulin sensitivity than either intervention alone.

Behavioral strategies, such as self-monitoring of food intake, structured meal planning, and support from registered dietitians or health coaches, can improve adherence. While lifestyle change can be challenging, the evidence is clear: even modest improvements can have a profound impact on metabolic outcomes. In many women with PCOS and prediabetes, lifestyle intervention is the only therapy needed to normalize blood glucose levels. Sleep optimization and stress management should also be addressed, as both sleep deprivation and chronic stress can worsen insulin resistance through cortisol-mediated mechanisms.

Pharmacological Options

For women who do not achieve adequate glucose control through lifestyle alone, or for those who are at particularly high risk—such as those with BMI > 30, history of gestational diabetes, or strong family history of diabetes—pharmacotherapy should be considered. Metformin is the most widely studied and commonly prescribed agent for prediabetes in PCOS. It works by reducing hepatic glucose production, improving peripheral insulin sensitivity, and lowering circulating insulin levels. Metformin has been shown to reduce the incidence of type 2 diabetes in high-risk populations by 31% in landmark trials such as the Diabetes Prevention Program. In women with PCOS, it also modestly reduces androgen levels, improves menstrual cyclicity, and can aid in weight loss. The typical starting dose is 500 mg once daily, titrated up to 1500-2000 mg per day as tolerated, with extended-release formulations often improving gastrointestinal tolerability.

Other medications are under investigation. Thiazolidinediones (TZDs) such as pioglitazone improve insulin sensitivity but carry concerns regarding weight gain, fluid retention, and potential cardiovascular risks. Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., liraglutide, semaglutide) are increasingly used in PCOS for their effects on weight reduction and glucose control, and early studies show promise for improving both metabolic and reproductive outcomes. Semaglutide, in particular, has demonstrated significant weight loss benefits in women with PCOS and obesity, and ongoing trials are evaluating its effects on ovulation and androgen levels. However, these agents are more expensive and not yet approved specifically for prediabetes or PCOS in all countries. Acarbose, an alpha-glucosidase inhibitor, can also be used to blunt postprandial glucose excursions but is less well tolerated due to gastrointestinal side effects.

Monitoring and Long-Term Management

Women with PCOS should undergo regular screening for prediabetes and diabetes, especially if they have additional risk factors. The American Diabetes Association recommends screening for diabetes and prediabetes in all overweight or obese women with PCOS who have additional risk factors, and in all women with PCOS starting at age 40, or earlier if they have a history of gestational diabetes. The hemoglobin A1c test is convenient, but the oral glucose tolerance test is more sensitive for detecting impaired glucose tolerance, which is the most common form of prediabetes in PCOS. Fasting glucose alone will miss approximately 50% of cases of impaired glucose tolerance, so the OGTT should be considered in high-risk populations.

Beyond blood glucose, comprehensive management should include monitoring of lipid profiles, blood pressure, and liver enzymes. Because cardiovascular disease is the leading cause of death in women with PCOS, early identification and treatment of dyslipidemia and hypertension are important. A multidisciplinary team—including a primary care physician, endocrinologist, registered dietitian, and possibly a reproductive endocrinologist—can provide coordinated care that addresses both metabolic and reproductive health. Regular follow-up every six to twelve months is recommended to track progress and adjust treatment as needed. Annual screening for type 2 diabetes should continue even if glucose levels are normal, as the risk persists over time.

Conclusion

The connection between PCOS and prediabetes is a clinical reality that demands attention. The interplay of insulin resistance, hyperinsulinemia, and androgen excess creates a metabolic environment that significantly raises the risk of type 2 diabetes, cardiovascular disease, and other endocrine complications. However, this link also provides an opportunity. Prediabetes is a reversible condition. With early detection and evidence-based interventions—focused on lifestyle modification, weight management, and, when necessary, pharmacotherapy—women with PCOS can reduce their risk of developing diabetes and improve their overall health outcomes. Recognizing the shared pathophysiology of PCOS and prediabetes empowers clinicians and patients to act before the window of prevention closes. For women with PCOS, understanding this connection is not merely academic; it is a crucial step toward taking control of their long-term metabolic health.

For further reading, the Endocrine Society's clinical practice guideline on PCOS offers comprehensive recommendations, while the American Diabetes Association provides resources on prediabetes screening and management. Additional insights into the metabolic risks of PCOS are available from the Mayo Clinic and the Eunice Kennedy Shriver National Institute of Child Health and Human Development.